OBJECTIVE: Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor that controls lipid metabolism and inflammation. PPARα is activated by fibrates, hypolipidemic drugs used in the treatment of dyslipidemia. Previous studies assessing the influence of PPARα agonists on atherosclerosis in mice yielded conflicting results, and the implication of PPARα therein has not been assessed. The human apolipoprotein E2 knock-in (apoE2-KI) mouse is a model of mixed dyslipidemia, atherosclerosis, and nonalcoholic steatohepatitis (NASH). The aim of this study was to analyze, using homo- and heterozygous PPARα-deficient mice, the consequences of quantitative variations of PPARα gene levels and their response to the synthetic PPARα agonist fenofibrate on NASH and atherosclerosis in apoE2-KI mice. METHODS AND RESULTS: Wild-type (+/+), heterozygous (+/-), and homozygous (-/-) PPARα-deficient mice in the apoE2-KI background were generated and subjected to a Western diet supplemented with fenofibrate or not supplemented. Western diet-fed PPARα-/- apoE2-KI mice displayed an aggravation of liver steatosis and inflammation compared with PPARα+/+ and PPARα+/- apoE2-KI mice, indicating a role of PPARα in liver protection. Moreover, PPARα expression was required for the fenofibrate-induced protection against NASH. Interestingly, fenofibrate treatment induced a similar response on hepatic lipid metabolism in PPARα+/+ and PPARα+/- apoE2-KI mice, whereas, for a maximal antiinflammatory response, both alleles of the PPARα gene were required. Surprisingly, atherosclerosis development was not significantly different among PPARα+/+, PPARα+/-, and PPARα-/- apoE2-KI mice. However, PPARα gene level determined both the antiatherosclerotic and vascular antiinflammatory responses to fenofibrate in a dose-dependent manner. CONCLUSIONS: These results demonstrate a necessary but quantitatively different role of PPARα in the modulation of liver metabolism, inflammation, and atherogenesis.
OBJECTIVE: Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor that controls lipid metabolism and inflammation. PPARα is activated by fibrates, hypolipidemic drugs used in the treatment of dyslipidemia. Previous studies assessing the influence of PPARα agonists on atherosclerosis in mice yielded conflicting results, and the implication of PPARα therein has not been assessed. The human apolipoprotein E2 knock-in (apoE2-KI) mouse is a model of mixed dyslipidemia, atherosclerosis, and nonalcoholic steatohepatitis (NASH). The aim of this study was to analyze, using homo- and heterozygous PPARα-deficient mice, the consequences of quantitative variations of PPARα gene levels and their response to the synthetic PPARα agonist fenofibrate on NASH and atherosclerosis in apoE2-KI mice. METHODS AND RESULTS: Wild-type (+/+), heterozygous (+/-), and homozygous (-/-) PPARα-deficient mice in the apoE2-KI background were generated and subjected to a Western diet supplemented with fenofibrate or not supplemented. Western diet-fed PPARα-/- apoE2-KI mice displayed an aggravation of liver steatosis and inflammation compared with PPARα+/+ and PPARα+/- apoE2-KI mice, indicating a role of PPARα in liver protection. Moreover, PPARα expression was required for the fenofibrate-induced protection against NASH. Interestingly, fenofibrate treatment induced a similar response on hepatic lipid metabolism in PPARα+/+ and PPARα+/- apoE2-KI mice, whereas, for a maximal antiinflammatory response, both alleles of the PPARα gene were required. Surprisingly, atherosclerosis development was not significantly different among PPARα+/+, PPARα+/-, and PPARα-/- apoE2-KI mice. However, PPARα gene level determined both the antiatherosclerotic and vascular antiinflammatory responses to fenofibrate in a dose-dependent manner. CONCLUSIONS: These results demonstrate a necessary but quantitatively different role of PPARα in the modulation of liver metabolism, inflammation, and atherogenesis.
Authors: P Gervois; I P Torra; G Chinetti; T Grötzinger; G Dubois; J C Fruchart; J Fruchart-Najib; E Leitersdorf; B Staels Journal: Mol Endocrinol Date: 1999-09
Authors: Vasilios G Athyros; Dimitri P Mikhailidis; Triandafillos P Didangelos; Olga I Giouleme; Evangelos N Liberopoulos; Asterios Karagiannis; Anna I Kakafika; Konstantinos Tziomalos; Andrew K Burroughs; Moses S Elisaf Journal: Curr Med Res Opin Date: 2006-05 Impact factor: 2.580
Authors: Kristiaan Wouters; Ronit Shiri-Sverdlov; Patrick J van Gorp; Marc van Bilsen; Marten H Hofker Journal: Clin Chem Lab Med Date: 2005 Impact factor: 3.694
Authors: Vladimir R Babaev; Hiroyuki Ishiguro; Lei Ding; Patricia G Yancey; Dwayne E Dove; William J Kovacs; Clay F Semenkovich; Sergio Fazio; MacRae F Linton Journal: Circulation Date: 2007-08-27 Impact factor: 29.690
Authors: Rai Ajit K Srivastava; Ravi Jahagirdar; Salman Azhar; Somesh Sharma; Charles L Bisgaier Journal: Mol Cell Biochem Date: 2006-02-14 Impact factor: 3.396
Authors: Michael Boergesen; Thomas Åskov Pedersen; Barbara Gross; Simon J van Heeringen; Dik Hagenbeek; Christian Bindesbøll; Sandrine Caron; Fanny Lalloyer; Knut R Steffensen; Hilde I Nebb; Jan-Åke Gustafsson; Hendrik G Stunnenberg; Bart Staels; Susanne Mandrup Journal: Mol Cell Biol Date: 2011-12-12 Impact factor: 4.272
Authors: Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough Journal: Biochim Biophys Acta Date: 2016-03-04
Authors: Marian Kampschulte; Christiane Stöckl; Alexander C Langheinrich; Ulrike Althöhn; Rainer M Bohle; Gabriele A Krombach; Philipp Stieger; Yuri Churin; Sandra Kremer; Christian Dierkes; Timo Rath; Elke Roeb; Martin Roderfeld Journal: Lab Invest Date: 2014-09-08 Impact factor: 5.662